Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide in Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
NCT03936829Active, not recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Apr 2019
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in acquired lipodystrophy, type 1 diabetes mellitus (T1D) and panniculitis, sponsored by Children's Hospital of Fudan University. Primary endpoint: Average daily insulin dosage at 21 weeks. Started Apr 2019; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acquired lipodystrophytype 1 diabetes mellitus (T1D)panniculitis
Beyond the preview
Go deeper on NCT03936829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936829.